HCWB
HCW Biologics Inc.
$1.63
0.00%
$11.0M
No data for this timeframe.
Vol
Market Cap$11.0M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders3 funds
Inst. Value$16.0K
Inst. Activity0 buys / 1 sells
Insider Activity6B / 0S
Insider Net $$430.0K
Reddit Sentiment67° Warm
SEC Reports9
Press Releases2
Recent Activity
Jun 3, 2026
short_volume
Short Volume: HCWB — 67.0% short (0.4M / 0.6M)
Short: 429,752 | Exempt: 96,897 | TRF Vol: 641,813 | Short Ratio: 67.0% | Off-exchange volume (dark
Jun 1, 2026
SEC
Nasdaq Hearings Panel granted HCW Biologics an extension until July 29, 2026 to regain compliance with the $1 minimum bi
8-K — Impact 7/10
May 27, 2026
SEC
Two HCWB insiders (Director Garrett and CFO Byam) made open-market purchases totaling $270K on May 22, 2026, at $1.405/s
CLUSTER — Impact 6/10
May 27, 2026
SEC
HCW Biologics terminated its exclusive worldwide license with Wugen Inc. for ex vivo rights to HCW9201 and HCW9206, rega
8-K — Impact 6/10
May 22, 2026
Insider
Byam Rebecca bought 14,235 shares
Chief Financial Officer @ $1.41 ($20.0K)
May 22, 2026
Insider
Byam Rebecca bought 14,235 shares
Chief Financial Officer @ $0.00 ($0.00)
May 22, 2026
Insider
GARRETT SCOTT T bought 177,936 shares
Director @ $1.41 ($250.0K)
Inst.
WELLS FARGO & COMPANY/MN — TRIM
1,000 shares ($971.00)
Price Targets
$5.00
+206.7% upside
Strong Buy
Current $1.63
Low $5.00
Median $5.00
High $5.00
1 analysts
$5.00
$5.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Maxim Group | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.33 ▼ -65.0% | $-0.33 — $-0.33 | 95% YoY | 1 |
| Next Q | $-0.18 ▲ +14.3% | $-0.18 — $-0.18 | 91% YoY | 1 |
| Current FY | $-0.48 ▲ +50.0% | $-0.48 — $-0.48 | 95% YoY | 1 |
| Next FY | $-0.44 ▲ +20.0% | $-0.44 — $-0.44 | 8% YoY | 1 |
Latest Reports
BEARISH
8-K
7/10
Nasdaq Hearings Panel granted HCW Biologics an extension until July 29, 2026 to regain compliance with the $1 minimum bi
Jun 1, 2026
BULLISH
CLUSTER
6/10
Two HCWB insiders (Director Garrett and CFO Byam) made open-market purchases totaling $270K on May 22, 2026, at $1.405/s
May 27, 2026
BEARISH
Press
6/10
HCW Biologics priced a private placement of ~2.85M units at $1.405/unit, raising ~$4M in gross proceeds. The offering in
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $15.0K | NEW |
| WELLS FARGO & COMPANY/MN | $971.00 | TRIM |
| BANK OF AMERICA CORP | $11.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 22, 2026 | Byam Rebecca | BUY | $20.0K |
| May 22, 2026 | Byam Rebecca | BUY | $0.00 |
| May 22, 2026 | GARRETT SCOTT | BUY | $250.0K |
| May 22, 2026 | GARRETT SCOTT | BUY | $0.00 |
| May 22, 2026 | Wong Hing | BUY | $160.0K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
3 institutional holders with $16.0K total value (16,437 shares) as of 2025-Q4. Top holders: VANGUARD, WELLS, BANK. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 15,426 | $15.0K | 93.8% | NEW |
| 2 | WELLS FARGO & COMPANY/MN | 1,000 | $971.00 | 6.1% | TRIM -41.2% |
| 3 | BANK OF AMERICA CORP /DE/ | 11 | $11.00 | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | TRIM | 1,700 | 1,000 | -41.2% | $971.00 | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 15,426 | — | $57.1K | 2025-Q3 |
| UBS Group AG | EXIT | 9,518 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | NEW | — | 9,518 | — | $37.7K | 2025-Q2 |
| VANGUARD GROUP INC | EXIT | 243,158 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | DOUBLED | 37,677 | 243,158 | +545.4% | $68.6K | 2025-Q1 |
3 unique insiders with 6 transactions. Net insider value: $430.0K ($430.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 22, 2026 | Byam Rebecca | Chief Financial Officer | BUY | 14,235 | $1.41 | $20.0K |
| May 22, 2026 | Byam Rebecca | Chief Financial Officer | BUY | 14,235 | $0.00 | $0.00 |
| May 22, 2026 | GARRETT SCOTT T | Director | BUY | 177,936 | $1.41 | $250.0K |
| May 22, 2026 | GARRETT SCOTT T | Director | BUY | 177,936 | $0.00 | $0.00 |
| May 22, 2026 | Wong Hing C | Chief Executive Officer | BUY | 113,879 | $1.41 | $160.0K |
| May 22, 2026 | Wong Hing C | Chief Executive Officer | BUY | 113,879 | $0.00 | $0.00 |
9 SEC filing reports analyzed. Sentiment: 2 bullish, 4 bearish, 1 mixed, 2 neutral. Avg impact: 6.1/10.
BEARISH
8-K
7/10
Nasdaq Hearings Panel granted HCW Biologics an extension until July 29, 2026 to regain compliance wi
Jun 1, 2026
BULLISH
CLUSTER
6/10
Two HCWB insiders (Director Garrett and CFO Byam) made open-market purchases totaling $270K on May 2
May 27, 2026
BULLISH
8-K
6/10
HCW Biologics terminated its exclusive worldwide license with Wugen Inc. for ex vivo rights to HCW92
May 27, 2026
BEARISH
8-K
7/10
HCW Biologics entered into a securities purchase agreement to sell 2,846,975 shares of common stock
May 21, 2026
BEARISH
PRESS-RELEASE
7/10
HCW Biologics reported Q1 2026 GAAP net income of $3.5M ($0.37 EPS), a dramatic swing from a $2.2M l
May 14, 2026
BEARISH
8-K
7/10
HCW Biologics reported Q1 2026 net income of $3.5M vs a $2.2M loss in Q1 2025, driven by $6.5M in re
May 14, 2026
NEUTRAL
8-K
4/10
HCW Biologics disclosed two consulting agreements totaling $3.0 million, both contingent on the clos
Apr 30, 2026
NEUTRAL
S-1/A
5/10
HCW Biologics Inc. is conducting an IPO amendment to raise up to $5.6 million through the issuance o
Apr 24, 2026
MIXED
8-K
6/10
HCW Biologics reported a net loss of $3.4M for Q4 2025, missing EPS estimates by 625% due to a $1.5M
Apr 21, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.00 mean target
+206.7% upside
Strong Buy (2.00)
$5.00 Low
$5.00 High
| Metric | Value |
|---|---|
| Current Price | $1.63 |
| Target Low | $5.00 |
| Target Mean | $5.00 |
| Target Median | $5.00 |
| Target High | $5.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.33 | $-0.33 | $-0.33 | 95.1% | -65.0% | 0↑ 1↓ | $0.0B | -100.0% | 1 |
| Next Q 2026-09-30 |
$-0.18 | $-0.18 | $-0.18 | 91.1% | +14.3% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Current FY 2026-12-31 |
$-0.48 | $-0.48 | $-0.48 | 95.5% | +50.0% | 1↑ 0↓ | $0.0B | 11965.3% | 1 |
| Next FY 2027-12-31 |
$-0.44 | $-0.44 | $-0.44 | 8.3% | +20.0% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.330 | |
| 7d ago | $-0.200 | -0.130 |
| 30d ago | $-0.200 | -0.130 |
| 60d ago | $-0.200 | -0.130 |
| 90d ago | $-0.240 | -0.090 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Maxim Group | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
5 mentions
4 bullish
1 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 15, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 15, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 13, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
HCWB - 3 Insiders Buys Today
▲ 1
💬 1
⚡ 0.5
$HCWB DROP 21%
▲ 4
💬 2
⚡ 0.0
Jun 3, 2026
short_volume
Short Volume: HCWB — 67.0% short (0.4M / 0.6M)
Short: 429,752 | Exempt: 96,897 | TRF Vol: 641,813 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: HCWB — 55.8% short (0.6M / 1.0M)
Short: 575,509 | Exempt: 86,916 | TRF Vol: 1,032,266 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: HCWB — 64.7% short (0.9M / 1.4M)
Short: 910,574 | Exempt: 14,030 | TRF Vol: 1,407,755 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: HCWB — 60.5% short (0.8M / 1.3M)
Short: 782,598 | Exempt: 4,311 | TRF Vol: 1,294,088 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
<p align="center"><em>Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market</em></p>
May 21, 2026
offering
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
<p>MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharma
May 20, 2026
short_volume
Short Volume: HCWB — 60.8% short (53.4M / 87.8M)
Short: 53,397,445 | Exempt: 14,807,439 | TRF Vol: 87,800,756 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: HCWB — 60.7% short (2.8M / 4.5M)
Short: 2,756,856 | Exempt: 180,282 | TRF Vol: 4,541,708 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: HCWB — 57.0% short (91.7M / 161.0M)
Short: 91,747,644 | Exempt: 726,889 | TRF Vol: 160,959,528 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
<p align="justify">MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-
May 14, 2026
fda
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
<p align="center"><em>HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senes
Apr 30, 2026
activist
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
<p align="justify">MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinic
Apr 27, 2026
other
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
<p align="center"><em>Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-p
Apr 27, 2026
short_volume
Short Volume: HCWB — 57.3% short (2.0M / 3.5M)
Short: 2,008,380 | Exempt: 149,394 | TRF Vol: 3,502,604 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
earnings
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
<p align="justify">MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinica